Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Results from an ongoing trial of 228 patients with acute major bleeding show that patients taking andexanet experienced a reduction in anti-FXa activity

In patients presenting with acute major bleeding after taking a Factor Xa (FXa) inhibitor, an infusion of the FXa inhibitor reversal agent, andexanet, resulted in a 92% median reduction in anti-FXa activity

Source  Biophoto Associates / Science Photo Library